Global Nonalcoholic Steatohepatitis (NASH) Market: Snapshot
Nonalcoholic Steatohepatitis (NASH), a syndrome found in non-alcoholic patients, causes damage to liver that is histologically akin to alcoholic hepatitis. NASH results from fat in the liver, along with inflammation. Symptoms in NASH usually do not show, but it can be severe and lead to cirrhosis, which is permanent damage to the liver.
Those suffering from obesity, dyslipidemia, and glucose intolerance are most likely to have nonalcoholic steatohepatitis (NASH). Most patients are asymptomatic and biopsy is essential to confirm the diagnosis. Treatment mainly entails elimination of causes and risk factors.
This 65 page report gives readers a comprehensive overview of the nonalcoholic steatohepatitis therapeutics market. Browse to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/nonalcoholic-steatohepatitis-market.html
Driving the growth in the global market for nonalcoholic steatohepatitis therapeutics is the rising instances of obesity and diabetes. Another factor boosting the market is the thrust on research and development. In fact, a noticeable trend in the market has been the focus on developing novel therapeutics for the curing NASH by big biopharmaceutical manufacturing companies. Propelled by such factors, the global market for nonalcoholic steatohepatitis therapeutics is slated to expand at a robust 10.7% CAGR between 2015 and 2025 to attain a value of US$20.27 bn by 2025.
Elafibranor Drug Holds a Sway over Market by Dint of being Most Advanced
The cause for nonalcoholic steatohepatitis (NASH) is unclear and research is being carried out to find effective treatments. At present, treatment of NASH focuses on controlling some of the medical conditions associated with it such as diabetes and obesity and monitoring for advancement. As with nonalcoholic fatty liver disease, people with NASH should be vaccinated against hepatitis A and B if they are not immune already.
Depending upon the type of drug, the global market for nonalcoholic steatohepatitis (NASH) can be segregated into potential phase III candidates such as Saroglitazar, Obeticholic acid (OCA), Aramchol, and Elafibranor. There are others too in the Phase I and Phase II clinical trials. Among the different types of drugs Elafibranor is predicted to hold maximum share in the market and also exhibit maximum growth rate. This is because Elafibranor is the most advanced drug in this category. It is followed by Obeticholic Acid (OCA) in the market.
Currently, Intercept Pharmaceuticals, in collaboration with DSP, is developing obeticholic acid for commercialization in the United States and European countries. This drug is anticipated to receive commercial approval by the end 2017.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving nonalcoholic steatohepatitis therapeutics market during 2015 – 2025: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=7691
Developing Nations Power Growth in Asia Pacific Market
While the prevalence of nonalcoholic steatohepatitis (NASH) is growing across the globe, it is the developed regions of Europe and North America that are seeing maximum instances on account of increasing occurrence of lifestyle related conditions such as obesity and diabetes. In North America particularly, the rate of obesity has almost doubled in children. Obesity also leads to diabetes and high blood cholesterol, which can aggravate health issues of those suffering from NASH.
In Europe, nonalcoholic steatohepatitis (NASH) is most prevalent in the countries of Spain, Germany, Italy, France and, the U.K. Developing economies, especially in Asia-Pacific are considered high growth markets for nonalcoholic steatohepatitis (NASH) therapeutics and are forecasted to grow at double digits in the foreseeable future. This is because of the alarming increase in nonalcoholic fatty liver diseases in countries of Korea, China, and Japan.
Some of the prominent names operating in the global market for nonalcoholic steatohepatitis (NASH) are Astazeneca Plc., Intercept Pharmaceuticals Inc., Galmed Pharmaceuticals Ltd., GENFIT SA, Gilead Sciences, Inc., Zydus Cadila, Immuron Ltd., Conatus Pharmaceuticals, and Tobira Therapeutics, Inc.